ARDX
Ardelyx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.46B
P/E Ratio
—
EPS
$-0.26
Beta
0.66
52W High
$8.40
52W Low
$3.21
50-Day MA
$6.49
200-Day MA
$5.78
Dividend Yield
—
Profit Margin
-15.10%
Forward P/E
33.00
PEG Ratio
-0.08
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Fundamentals
| Revenue (TTM) | $407.32M |
| Gross Profit (TTM) | $296.26M |
| EBITDA | $-37.92M |
| Operating Margin | 4.07% |
| Return on Equity | -36.20% |
| Return on Assets | -5.46% |
| Revenue/Share (TTM) | $1.69 |
| Book Value | $0.68 |
| Price-to-Book | 8.74 |
| Price-to-Sales (TTM) | 3.60 |
| EV/Revenue | 3.443 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.80% |
| Shares Outstanding | $245.25M |
| Float | $222.58M |
| % Insiders | 2.82% |
| % Institutions | 69.59% |
Analyst Ratings
Consensus ($16.10 target)
1
Strong Buy10
BuyData last updated: 4/7/2026